Despite a mixed fourth-quarter revenue performance, British pharmaceutical giant GSK remains optimistic about its long-term growth prospects, particularly with its ambitious revenue target for 2031.

The FDA has also approved glatopa, a generic form of Copaxone. Natalizumab (Tysabri) is an infused medication that may block damaged T lymphocytes from entering the brain and spinal cord.

In October, when GSK agreed to a $2.2 billion settlement to resolve approximately 80,000 lawsuits brought by users of Zantac, it appeared that the drugmaker’s legal issues with the heartburn ...

Although lifestyle changes can help you remove these risks and control your blood pressure without medication, you should not stop taking blood pressure medication without first discussing it with ...

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE: GSK) between ...

In 2019, independent laboratory Valisure found NDMA, a cancer-causing poison, in "every batch of every [Zantac] medication" that it tested. Valisure reported these results to the U.S. Food and ...

Global pharmaceutical company GSK Plc allegedly deceived investors when it concealed for decades an internal study implicating a link between the heartburn drug Zantac and cancer, a proposed class ...